Form **990-PF**

Return of Private Foundation

or Section 4947(a)(1) Trust Treated as Private Foundation

Department of the Treasury

▶ Do not enter social security numbers on this form as it may be made public.

Internal Revenue Service ► Information about Form 990-PF and its separate instructions is at www.irs.gov/form990pf.

For calendar year 2015 or tax year beginning July 1 2015, and ending June

OMB No. 1545-0052 Open to Public Inspection

	me of for	uar year 2015 or tax year be	girining		2015, al	na enaing	u identification numbe	, 20 10
		e Research Foundation, Inc.				A Employe	r identification number 87 0790903	er
		d street (or P.O. box number if mail is a	not delivered to street address)	T	Room/suite	e B Telephon	e number (see instructi	one)
		y Lake Court	not delivered to street address;		1100III/Suite	e B releption	612-840-5881	0113)
		n, state or province, country, and ZIP of	or foreign postal code					
	•	iks, MN 55127-6219	or foreign postar oode			C If exempt	ion application is pendi	ing, check here ►
G	Check	all that apply: Initial retu	urn Initial return	of a former p	ublic cha	arity D 1. Foreign	n organizations, check l	here ▶
		☐ Final retu						
		Address	change 🔲 Name char	nge			n organizations meeting here and attach compu	
Н	Check	type of organization: 🗾 Se	ection 501(c)(3) exempt p	rivate founda	tion	E If private	foundation status was	terminated under
		n 4947(a)(1) nonexempt charit				section 5	07(b)(1)(A), check here	▶□
		narket value of all assets at				ıal	ndation is in a 60-montl	n termination
	end of	year (from Part II, col. (c),	Other (specify)			under sec	ction 507(b)(1)(B), check	chere ►
	line 16	f) ► \$ 1,327,388	(Part I, column (d) must be	on cash basis)			
P	art I	Analysis of Revenue and Ex	xpenses (The total of	(a) Revenue a	and			(d) Disbursements
		amounts in columns (b), (c), and (d)		expenses p		Net investment income	(c) Adjusted net income	for charitable purposes
		the amounts in column (a) (see instr	ructions).)	books				(cash basis only)
	1	Contributions, gifts, grants, etc.,		112	2,460			
	2	Check ► ☐ if the foundation is n	•					
	3	Interest on savings and temp	-		531	531	531	
	4	Dividends and interest from s		16	5,811	5,642	5,642	
	5a	Gross rents			-0-	-0-	-0-	
	b	Net rental income or (loss)	-0-	0/	2.000			
Revenue	6a	Net gain or (loss) from sale of		22	2,689			
Je.	b	Gross sales price for all assets on				27,125		
ě	7	Capital gain net income (from				27,125	-0-	
_	8	Net short-term capital gain . Income modifications					-0-	
	10a	Gross sales less returns and allo	wances -0-				-0-	
	b	Less: Cost of goods sold .						
	C	Gross profit or (loss) (attach			-0-		-0-	
	11	Other income (attach schedu			-0-	-0-	-0-	
	12	Total. Add lines 1 through 11		152	2,490	33,298	6,173	
<u></u>	13	Compensation of officers, dir			-0-	-0-	-0-	-0-
Se	14	Other employee salaries and	wages		-0-	-0-	-0-	-0-
en	15	Pension plans, employee ber	nefits		-0-	-0-	-0-	-0-
Expenses	16a	Legal fees (attach schedule)		Stmt 1: 31	,214	-0-	-0-	31,214
(D)	b	Accounting fees (attach sche			-0-	-0-	-0-	-0-
نٍ	C	Other professional fees (attack			-0-	-0-	-0-	-0-
tra	17			011.0	-0-	-0-	-0-	-0-
nis	18	Taxes (attach schedule) (see ins	-	Stmt 2:	0,703	9,703	9,703	-0-
Ξ	19	Depreciation (attach schedul			-0-	-0- -0-	-0- -0-	-0-
Ad	20	Occupancy			5,997	-0-	-0-	6,997
pu	21 22	Travel, conferences, and med Printing and publications .	etings		3.475	-0-	-0-	3,475
a	23	Other expenses (attach sche			2,750	8	8	2,742
ij	24	Total operating and adm						_,
Operating and Administrative		Add lines 13 through 23						
be	25	Contributions, gifts, grants p		76	6,259			76,259
0	26	Total expenses and disbursem		130),399	9,711	9,711	120,687
	27	Subtract line 26 from line 12:						
	а	Excess of revenue over exper	ses and disbursements	22	2,092			
	b	Net investment income (if n				23,587		
	С	Adjusted net income (if neg	ative, enter -0-)				-0-	
								000 DE

Page 2

New Hope Research Foundation — 87 0790903

D,	art II	Rolongo Shoots Attached schedules and amounts in the description column	Beginning of year	End o	of year
Г	art II	Balance Sheets Attached schedules and amounts in the description column should be for end-of-year amounts only. (See instructions.)	(a) Book Value (b) Book Value	(c) Fair Market Value
	1	Cash—non-interest-bearing	-0-	-0-	-0-
	2	Savings and temporary cash investments	322,346	676,200	676,200
	3	Accounts receivable ► None			
		Less: allowance for doubtful accounts ▶ None	-0-	-0-	-0-
	4	Pledges receivable ► None			
		Less: allowance for doubtful accounts ▶ None	-0-	-0-	-0-
	5	Grants receivable	-0-	-0-	-0-
	6	Receivables due from officers, directors, trustees, and other			
		disqualified persons (attach schedule) (see instructions)	-0-	-0-	-0-
	7	Other notes and loans receivable (attach schedule) ► None			
		Less: allowance for doubtful accounts ▶ None	-0-	-0-	-0-
ţ	8	Inventories for sale or use	-0-	-0-	-0-
Assets	9	Prepaid expenses and deferred charges	-0-	-0-	-0-
Ä	10a	Investments—U.S. and state government obligations (attach schedule)	-0-	-0-	-0-
	b	Investments—corporate stock (attach schedule)	Stmt 4: 792,585	538,168	603,533
	С	Investments—corporate bonds (attach schedule)	-0-		
	11	Investments—land, buildings, and equipment: basis ▶None			
		Less: accumulated depreciation (attach schedule) ▶None	-0-	-0-	-0-
	12	Investments – mortgage loans	-0-	-0-	-0-
	13	Investments—other (attach schedule)	Stmt 5: 125,000	-0-	-0-
	14	Land, buildings, and equipment: basis ► Stereotaxic Unit: \$1,945.00			
		Less: accumulated depreciation (attach schedule) ▶ -0-	-0-	1,945	1,945
	15	Other assets (describe ► US Patent Appl 15/145,293)	-0-	45,710	45,710
	16	Total assets (to be completed by all filers-see the			
		instructions. Also, see page 1, item I)	1,239,931	1,262,023	1,327,388
	17	Accounts payable and accrued expenses	-0-	-0-	
S	18	Grants payable	-0-	-0-	
Liabilities	19	Deferred revenue	-0-	-0-	
Ξ	20	Loans from officers, directors, trustees, and other disqualified persons	-0-	-0-	
<u>ia</u>	21	Mortgages and other notes payable (attach schedule)	-0-	-0-	
_	22	Other liabilities (describe ► None)	-0-	-0-	
	23	Total liabilities (add lines 17 through 22)	-0-	-0-	
Balances		Foundations that follow SFAS 117, check here and complete lines 24 through 26 and lines 30 and 31. ▶ □			
Ē	24	Unrestricted			
ale	25	Temporarily restricted			
	26	Permanently restricted			
Net Assets or Fund		Foundations that do not follow SFAS 117, check here ▶ and complete lines 27 through 31.			
ō	27	Capital stock, trust principal, or current funds	-0-	-0-	
ts	28	Paid-in or capital surplus, or land, bldg., and equipment fund	-0-	-0-	
Se	29	Retained earnings, accumulated income, endowment, or other funds	1,239,931	1,262,023	
As	30	Total net assets or fund balances (see instructions)	1,239,931	1,262,023	
<u>let</u>	31	Total liabilities and net assets/fund balances (see			
Z		instructions)	1,239,931	1,262,023	
Pa	rt III	Analysis of Changes in Net Assets or Fund Balances			
	Tota	Il net assets or fund balances at beginning of year-Part II, colu			
	end-	of-year figure reported on prior year's return)		1	1,239,931
2	2 Ente	er amount from Part I, line 27a		2	22,092
3		er increases not included in line 2 (itemize)			-0-
4	Add	lines 1, 2, and 3		4	1,262,023
5	· D	venera met ingluded in line O (itemains)			-0-
6	Tota	reases not included in line 2 (itemize) $ ightharpoonup$ Il net assets or fund balances at end of year (line 4 minus line 5)—I	Part II, column (b), line 30) · · 6	1,262,023

Part	V Capital Gains and	Losses for Tax on Investm	ent Income			
		e kind(s) of property sold (e.g., real estate se; or common stock, 200 shs. MLC Co.)	,	(b) How acquired P-Purchase D-Donation	(c) Date acquired (mo., day, yr.)	(d) Date sold (mo., day, yr.)
1a	Common Stock, Medtronic Pl	LC, 186 shares		Р	01/27/2015	04/25/2015
b	Common Stock, Medtronic Pl	· ·		Р	01/27/2015	04/26/2016
c	Common Stock, Medtronic Pl	<u>'</u>		Р	01/27/2015	05/16/2015
d	Certificate of Deposit, Goldma	an Sachs, \$125,000 face		Р	04/29/2015	04/29/2016
е						
	(e) Gross sales price	(f) Depreciation allowed (or allowable)		other basis nse of sale		ain or (loss) (f) minus (g)
a	14,834	-0-		14,282		552
b	224,416	-0-		214,749		9,667
c	245,850	-0-		228,944		16,906
d	125,000	-0-		125,000		0.00
<u>е</u>	0 11 16			10/01/00		
	(i) F.M.V. as of 12/31/69	wing gain in column (h) and owned b (j) Adjusted basis as of 12/31/69	(k) Exces	on 12/31/69 s of col. (i) (j), if any	col. (k), but n	ol. (h) gain minus ot less than -0-) or (from col. (h))
а						552
b						9,667
С						16,906
d						0.00
е						
2	Capital gain net income or	r inat canital ineel ?	also enter in Pa enter -0- in Par		2	27,125
3	If gain, also enter in Part	n or (loss) as defined in sections I, line 8, column (c) (see instruc	tions). If (loss)			0
Part		er Section 4940(e) for Redu			3	-0-
If sect	ion 4940(d)(2) applies, leave	vate foundations subject to the sethis part blank. section 4942 tax on the distribut qualify under section 4940(e). De	able amount of	any year in the b	ŕ	☐ Yes 🕢 No
1	Enter the appropriate amo	ount in each column for each yea	r; see the instru	uctions before ma	aking any entries	
Cale	(a) Base period years endar year (or tax year beginning in)	(b) Adjusted qualifying distributions	Net value of	(c) f noncharitable-use as		(d) stribution ratio divided by col. (c))
	2014	140	,927	1,057	7,948	0.1332
	2013	136	,866	714	4,328	0.1916
	2012	104	,581	518	3,926	0.2015
	2011	57	,519	423	3,182	0.1359
	2010	11	,275	343	3,280	0.0328
2			de the total on I	ine 2 by 5, or by		0.6950 0.1390
4	Enter the net value of none	charitable-use assets for 2015 fr	om Part X, line	5	. 4	1,186,349
5	Multiply line 4 by line 3				. 5	147,055
6	Enter 1% of net investmen	nt income (1% of Part I, line 27b)			. 6	236
7	Add lines 5 and 6				. 7	147,291
8		ns from Part XII, line 4 ater than line 7, check the box in			. 8 hat part using a	120,687 1% tax rate. See the

Part '	Excise Tax Based on Investment Income (Section 4940(a), 4940(b), 4940(e), or 4948—see i	<u>nstru</u>	ıctioı	ns)			
1a	Exempt operating foundations described in section 4940(d)(2), check here \(\bigcup \) and enter "N/A" on line 1. Date of ruling or determination letter: (attach copy of letter if necessary—see instructions)						
b	Domestic foundations that meet the section 4940(e) requirements in Part V, check		471	74			
	here ► □ and enter 1% of Part I, line 27b						
С	All other domestic foundations enter 2% of line 27b. Exempt foreign organizations enter 4% of Part I, line 12, col. (b).						
2	2 Tax under section 511 (domestic section 4947(a)(1) trusts and taxable foundations only. Others enter -0-)						
3	3 Add lines 1 and 2						
4	Subtitle A (income) tax (domestic section 4947(a)(1) trusts and taxable foundations only. Others enter -0-)		0	00			
5	Tax based on investment income. Subtract line 4 from line 3. If zero or less, enter -0		471	74			
6	Credits/Payments:						
а	2015 estimated tax payments and 2014 overpayment credited to 2015 6a 0 00 Figure 1 to 1 t						
b	Exempt foreign organizations—tax withheld at source						
c d	Tax paid with application for extension of time to file (Form 8868) . 6c 0 00 Backup withholding erroneously withheld 6d 0 00						
7	Total credits and payments. Add lines 6a through 6d		0	00			
8	Enter any penalty for underpayment of estimated tax. Check here _ if Form 2220 is attached 8		0	00			
9	Tax due. If the total of lines 5 and 8 is more than line 7, enter amount owed		471	74			
10	Overpayment. If line 7 is more than the total of lines 5 and 8, enter the amount overpaid > 10		0	00			
11	Enter the amount of line 10 to be: Credited to 2016 estimated tax ► -0- Refunded ► 11		0	00			
Part '	VII-A Statements Regarding Activities						
1a	During the tax year, did the foundation attempt to influence any national, state, or local legislation or did it		Yes	No			
	participate or intervene in any political campaign?	1a		1			
b	Did it spend more than \$100 during the year (either directly or indirectly) for political purposes (see Instructions for the definition)?	1b		,			
	If the answer is "Yes" to 1a or 1b, attach a detailed description of the activities and copies of any materials						
	published or distributed by the foundation in connection with the activities.						
	Did the foundation file Form 1120-POL for this year?	1c		1			
d	Enter the amount (if any) of tax on political expenditures (section 4955) imposed during the year: (1) On the foundation. ▶ \$ None (2) On foundation managers. ▶ \$ None						
е	Enter the reimbursement (if any) paid by the foundation during the year for political expenditure tax imposed on foundation managers. ► \$ None						
2	Has the foundation engaged in any activities that have not previously been reported to the IRS?	2		•			
3	Has the foundation made any changes, not previously reported to the IRS, in its governing instrument, articles of incorporation, or bylaws, or other similar instruments? If "Yes," attach a conformed copy of the changes	3					
4a	Did the foundation have unrelated business gross income of \$1,000 or more during the year?	4a		1			
b	If "Yes." has it filed a tax return on Form 990-T for this year?	4b					
5	Was there a liquidation, termination, dissolution, or substantial contraction during the year?	5		1			
	If "Yes," attach the statement required by General Instruction T.						
6	Are the requirements of section 508(e) (relating to sections 4941 through 4945) satisfied either:						
	By language in the governing instrument, or						
	• By state legislation that effectively amends the governing instrument so that no mandatory directions that						
_	conflict with the state law remain in the governing instrument?	6	*				
7	Did the foundation have at least \$5,000 in assets at any time during the year? If "Yes," complete Part II, col. (c), and Part XV	7	*				
8a	Enter the states to which the foundation reports or with which it is registered (see instructions) ► Minnesota						
b	If the answer is "Yes" to line 7, has the foundation furnished a copy of Form 990-PF to the Attorney General (or designate) of each state as required by <i>General Instruction G? If "No," attach explanation</i>	8b	1				
9	Is the foundation claiming status as a private operating foundation within the meaning of section 4942(j)(3) or						
	4942(j)(5) for calendar year 2015 or the taxable year beginning in 2015 (see instructions for Part XIV)? If "Yes,"						
	complete Part XIV	9	*				
10	Did any persons become substantial contributors during the tax year? If "Yes," attach a schedule listing their names and addresses	10	1				

Part	VII-A Statements Regarding Activities (continued)			
			Yes	No
11	At any time during the year, did the foundation, directly or indirectly, own a controlled entity within the			
40	meaning of section 512(b)(13)? If "Yes," attach schedule (see instructions)	11		~
12	Did the foundation make a distribution to a donor advised fund over which the foundation or a disqualified person had advisory privileges? If "Yes," attach statement (see instructions)	40		
40		12		-
13	Did the foundation comply with the public inspection requirements for its annual returns and exemption application? Website address http://www.NewHopeResearch.org/financials.html	13	/	
14		2-840-	5881	
17	Leasted at N. 6 Charley Lake Court, North Oaks, MN. 71D. 4 N. 55	127-6		
15	Section 4947(a)(1) nonexempt charitable trusts filing Form 990-PF in lieu of Form 1041 —Check here			
10	and enter the amount of tax-exempt interest received or accrued during the year		•	N/A
16	At any time during calendar year 2015, did the foundation have an interest in or a signature or other authority		Yes	1
	over a bank, securities, or other financial account in a foreign country?	16		1
	See the instructions for exceptions and filing requirements for FinCEN Form 114. If "Yes," enter the name of			Ť
	the foreign country ► _{N/A}			
Part	VII-B Statements Regarding Activities for Which Form 4720 May Be Required			
	File Form 4720 if any item is checked in the "Yes" column, unless an exception applies.		Yes	No
1a	During the year did the foundation (either directly or indirectly):			
	(1) Engage in the sale or exchange, or leasing of property with a disqualified person?			
	(2) Borrow money from, lend money to, or otherwise extend credit to (or accept it from) a disqualified person?			
	disqualified person?			
	(4) Pay compensation to, or pay or reimburse the expenses of, a disqualified person? Yes No			
	(5) Transfer any income or assets to a disqualified person (or make any of either available for			
	the benefit or use of a disqualified person)?			
	(6) Agree to pay money or property to a government official? (Exception. Check "No" if the			
	foundation agreed to make a grant to or to employ the official for a period after			
	termination of government service, if terminating within 90 days.)			
b	If any answer is "Yes" to 1a(1)–(6), did any of the acts fail to qualify under the exceptions described in Regulations			
	section 53.4941(d)-3 or in a current notice regarding disaster assistance (see instructions)?	1b		
	Organizations relying on a current notice regarding disaster assistance check here			
С	Did the foundation engage in a prior year in any of the acts described in 1a, other than excepted acts, that			
2	were not corrected before the first day of the tax year beginning in 2015?	1c		/
2	Taxes on failure to distribute income (section 4942) (does not apply for years the foundation was a private operating foundation defined in section 4942(j)(3) or 4942(j)(5)): 2015 Private Operating Foundation			
а	At the end of tax year 2015, did the foundation have any undistributed income (lines 6d and			
	6e, Part XIII) for tax year(s) beginning before 2015?			
	If "Yes," list the years ▶ 20 , 20 , 20 , 20			
b	Are there any years listed in 2a for which the foundation is not applying the provisions of section 4942(a)(2)			
	(relating to incorrect valuation of assets) to the year's undistributed income? (If applying section 4942(a)(2) to all years listed, answer "No" and attach statement—see instructions.)	OI.		
•	If the provisions of section 4942(a)(2) are being applied to any of the years listed in 2a, list the years here.	2b		
С	► 20 , 20 , 20, 20			
3a	Did the foundation hold more than a 2% direct or indirect interest in any business enterprise			
	at any time during the year?			
b	If "Yes," did it have excess business holdings in 2015 as a result of (1) any purchase by the foundation or			
~	disqualified persons after May 26, 1969; (2) the lapse of the 5-year period (or longer period approved by the			
	Commissioner under section 4943(c)(7)) to dispose of holdings acquired by gift or bequest; or (3) the lapse of			
	the 10-, 15-, or 20-year first phase holding period? (Use Schedule C, Form 4720, to determine if the			
	foundation had excess business holdings in 2015.)	3b		
4a	Did the foundation invest during the year any amount in a manner that would jeopardize its charitable purposes?	4a		~
b	Did the foundation make any investment in a prior year (but after December 31, 1969) that could jeopardize its charitable purpose that had not been removed from jeopardy before the first day of the tax year beginning in 2015?	4.		
	chantable purpose that had not been removed from jeopardy before the first day of the tax year beginning in 2015?	4b		/

(2) Influence the outcome of any specific public election (see section 4955); or to carry on, directly or indirectly, any voter registration drive?		:d (continued)	Require	May Be R	Form 4720	or Whic	Activities	Statements Regarding Activi	t VII-B	Part
(2) Influence the outcome of any specific public election (see section 4955); or to carry on, directly or indirectly, any voter registration drive?						amount :	or incur ar	e year did the foundation pay or inc	During t	5a
directly or indirectly, any voter registration drive? (3) Provide a grant to an individual for travel, study, or other similar purposes? Yes No.	o	🗌 Yes 🛮 🗸 No	e))? .	ion 4945(e)	gislation (sec	nfluence	attempt to	on propaganda, or otherwise attem	(1) Carr	
(3) Provide a grant to an individual for travel, study, or other similar purposes?			arry on,	5); or to ca	e section 495	lection (s	cific public	nce the outcome of any specific p	(2) Influ	
(4) Provide a grant to an organization other than a charitable, etc., organization described in section 4945(d)(4)(A) (see instructions). □Yes № No.	o	🗌 Yes 🛮 🗸 No				?	stration dri	y or indirectly, any voter registratio	dire	
section 4945(d)(4)(A)? (see instructions).	o	🗌 Yes 🛮 🗸 No		es?	milar purpos	, or other	travel, stud	le a grant to an individual for travel,	(3) Prov	
(5) Provide for any purpose other than religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals?			ribed in	ation desc	etc., organiz	charitab	other than	le a grant to an organization other	(4) Prov	
(1) Carry on propaganda, or otherwise attempt to influence legislation (section 4945(e))?	o o									
During the year did the foundation pay or incur any amount to: (1) Carry on propaganda, or otherwise attempt to influence legislation (section 4945(e))? _ Yes										
During the year did the foundation pay or incur any amount to: (1) Carry on propaganda, or otherwise attempt to influence legislation (section 4945(e))?										
Organizations relying on a current notice regarding disaster assistance check here c If the answer is "Yes" to question 5a(4), does the foundation claim exemption from the tax because it maintained expenditure responsibility for the grant? N/A Yes Nc/A If "Yes," attach the statement required by Regulations section 53.4945–5(d). 6a Did the foundation, during the year, receive any funds, directly or indirectly, to pay premiums on a personal benefit contract? b Did the foundation, during the year, pay premiums, directly or indirectly, on a personal benefit contract? If "Yes" to 6b, file Form 8870. 7a At any time during the tax year, was the foundation a party to a prohibited tax shelter transaction? Yes No b If "Yes," did the foundation receive any proceeds or have any net income attributable to the transaction? No Information About Officers, Directors, Trustees, Foundation Managers, Highly Paid End and Contractors 1 List all officers, directors, trustees, foundation managers and their compensation (see instructions). (a) Name and address (b) Title, and average hours per week devoted to position (d) Contributions to employee benefit plans and deferred compensation (d) Contributions to employee benefit plans and deferred compensation (d) Contributions to employee benefit plans and deferred compensation (e) Chair / President 32 hours/wk -0- 6 Chairley Lake Court, North Oaks, MN 55127-6219 Board Member 210 Alexander Drive, Linwood, NJ 08221-1544 (a) Name and address of each employee paid more than \$50,000 (b) Title, and average hours per week devoted to position (c) Compensation (d) Contributions to employee benefit plans and deferred compensation (d) Contributions to employee benefit plans and deferred compensation plans and deferred compensation	n									b
c If the answer is "Yes" to question 5a(4), does the foundation claim exemption from the tax because it maintained expenditure responsibility for the grant?	/A 5b	^{1?} · · · · · · N/A	ructions)	•					•	
because it maintained expenditure responsibility for the grant?		· · · · —								
If "Yes," attach the statement required by Regulations section 53.4945–5(d). Calcal Did the foundation, during the year, receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?			the tax	otion from	claim exem	foundati	4), does th	wer is "Yes" to question 5a(4), do	If the ar	С
Did the foundation, during the year, receive any funds, directly or indirectly, to pay premiums on a personal benefit contract? Fart Vill Did the foundation, during the year, pay premiums, directly or indirectly, on a personal benefit contract? Fart Yes" to 6b, file Form 8870. At any time during the tax year, was the foundation a party to a prohibited tax shelter transaction? Yes Note Yes	0	Yes	N/A							
on a personal benefit contract? Yes No										_
b Did the foundation, during the year, pay premiums, directly or indirectly, on a personal benefit contract? If "Yes" to 6b, file Form 8870. 7a At any time during the tax year, was the foundation a party to a prohibited tax shelter transaction? Yes No If "Yes," did the foundation receive any proceeds or have any net income attributable to the transaction? Information About Officers, Directors, Trustees, Foundation Managers, Highly Paid E and Contractors 1 List all officers, directors, trustees, foundation managers and their compensation (see instructions). (a) Name and address (b) Title, and average hours per week devoted to position (c) Compensation (d) Contributions to employee benefit plans and deferred compensation (d) Contributions to employee benefit plans and deferred compensation (e) Chair / President 32 hours/wk -0- 6 Charley Lake Court, North Oaks, MN 55127-6219 Ellen L. Kraft (o) Chair (o) Compensation (o) Compensation (d) Contributions to employee benefit plans and deferred compensation 1 hour/month -0- 210 Alexander Drive, Linwood, NJ 08221-1544 (a) Name and address of each employee paid more than \$50,000 (b) Title, and average hours per week devoted to position (c) Compensation (d) Contributions to employee benefit plans and deferred compensation			emiums		-		-			6a
If "Yes" to 6b, file Form 8870. 7a At any time during the tax year, was the foundation a party to a prohibited tax shelter transaction?									-	
At any time during the tax year, was the foundation a party to a prohibited tax shelter transaction? Yes No If "Yes," did the foundation receive any proceeds or have any net income attributable to the transaction? No If "Yes," did the foundation receive any proceeds or have any net income attributable to the transaction? No If "Yes," did the foundation receive any proceeds or have any net income attributable to the transaction? No If "Yes," did the foundation receive any proceeds or have any net income attributable to the transaction? No If "Yes," did the foundation receive any proceeds or have any net income attributable to the transaction? No If "Yes," did the foundation receive any proceeds or have any net income attributable to the transaction? No If "Yes," did the foundation receive any proceeds or have any net income attributable to the transaction? No If If "Yes," did the foundation receive any proceeds or have any net income attributable to the transaction? No If If "Yes," did the foundation receive any proceeds or have any net income attributable to the transaction? No If If "Yes, If	6b 🗸	contract? .	ıl benefit	a personal	indirectly, on	directly	y premium			b
If "Yes," did the foundation receive any proceeds or have any net income attributable to the transaction? .N. Information About Officers, Directors, Trustees, Foundation Managers, Highly Paid E and Contractors List all officers, directors, trustees, foundation managers and their compensation (see instructions). (a) Name and address (b) Title, and average hours per week devoted to position (f) Compensation (fi not paid, enter -0-) (d) Contributions to employee benefit plans and deferred compensation (d) Contributions to employee benefit plans and deferred compensation (d) Contributions to employee benefit plans and deferred compensation (d) Contributions to employee benefit plans and deferred compensation (d) Contributions to employee benefit plans and deferred compensation (d) Contributions to employee benefit plans and deferred compensation (d) Contributions to employee benefit plans and deferred compensation (d) Contributions to employee benefit plans and deferred compensation (e) Compensation (f) Title, and average hours per week devoted to position (h) Title, and average hours per week devoted to position (h) Title, and average hours per week devoted to position (h) Title, and average hours per week devoted to position (h) Title, and average hours per week devoted to position (h) Title, and average hours per week devoted to position (h) Title, and average hours per week devoted to position		□Vaa □Na	ation O	altau tuanaa	مام برمة لممائطانط	aut. ta a r	dation a	•		7-
Information About Officers, Directors, Trustees, Foundation Managers, Highly Paid E and Contractors 1 List all officers, directors, trustees, foundation managers and their compensation (see instructions). (a) Name and address (b) Title, and average hours per week devoted to position (fi not paid, enter -0-) (d) Contributions to employee benefit plans and deferred compensation (fi not paid, enter -0-) (d) Contributions to employee benefit plans and deferred compensation (fi not paid, enter -0-) (d) Contributions to employee benefit plans and deferred compensation (fi not paid, enter -0-) (d) Contributions to employee benefit plans and deferred compensation (fi not paid, enter -0-) (fi not paid, ente										
and Contractors 1 List all officers, directors, trustees, foundation managers and their compensation (see instructions). (a) Name and address (b) Title, and average hours per week devoted to position (If not paid, enter -0-) (If not paid, ente										
1 List all officers, directors, trustees, foundation managers and their compensation (see instructions). (a) Name and address (b) Title, and average hours per week devoted to position (c) Compensation (ff not paid, enter -0-) (d) Contributions to employee benefit plans and deferred compensation (d) Contributions to employee benefit plans and deferred compensation (a) Name and address (b) Title, and average devoted to position (c) Compensation (d) Contributions to employee benefit plans and deferred compensation (d) Contributions to employee benefit plans and deferred compensation (d) Contributions to employee benefit plans and deferred compensation (d) Contributions to employee benefit plans and deferred compensation (d) Contributions to employee benefit plans and deferred compensation (e) Compensation (fin tot paid, enter -0-) (f	inipio y o o o,	inginy i aia En	ugo.o,	tion man	oo, i ouiiuu	io, iiuo	, D., OC.	•		ı aıı
(a) Name and address (b) Title, and average hours per week devoted to position John G. Keimel Chair / President 32 hours/wk Chair / President 32 hours/wk Chair / O- Chai		nstructions).	n (see ir	npensation	nd their cor	nanagers	oundation		List all	1
devoted to position enter -0-) and deferred compensation	(e) Expense account.	Contributions to	(d) (mpensation	erage (c) Co) Title, and				
32 hours/wk -0- 6 Charley Lake Court, North Oaks, MN 55127-6219 Ellen L. Kraft Vice Chair 0.5 hours/wk -0- 6 Charley Lake Court, North Oaks, MN 55127-6219 Raymond S. Schreyer, MD 210 Alexander Drive, Linwood, NJ 08221-1544 2 Compensation of five highest-paid employees (other than those included on line 1—see instruction "NONE." (a) Name and address of each employee paid more than \$50,000 (b) Title, and average hours per week devoted to position (c) Compensation (d) Contributions to employee benefit plans and deferred compensation	adhau allauranaaa	yee benefit plans 1.	and defe					(a) Name and address		
6 Charley Lake Court, North Oaks, MN 55127-6219 Ellen L. Kraft 6 Charley Lake Court, North Oaks, MN 55127-6219 Raymond S. Schreyer, MD 210 Alexander Drive, Linwood, NJ 08221-1544 Compensation of five highest-paid employees (other than those included on line 1—see instruction "NONE." (a) Name and address of each employee paid more than \$50,000 (b) Title, and average hours per week devoted to position (c) Compensation (d) Contributions to employee benefit plans and deferred compensation	0-	0		0	nt				G. Keimel	John G
6 Charley Lake Court, North Oaks, MN 55127-6219 Raymond S. Schreyer, MD 210 Alexander Drive, Linwood, NJ 08221-1544 Compensation of five highest-paid employees (other than those included on line 1—see instruction "NONE." (a) Name and address of each employee paid more than \$50,000 (b) Title, and average hours per week devoted to position (c) Compensation (d) Contributions to employee benefit plans and deferred compensation	-0-	-0-		-0-		hours/wk	19	Court, North Oaks, MN 55127-6219	narley Lake	6 Ch
6 Charley Lake Court, North Oaks, MN 55127-6219 Raymond S. Schreyer, MD 210 Alexander Drive, Linwood, NJ 08221-1544 Compensation of five highest-paid employees (other than those included on line 1—see instruction "NONE." (a) Name and address of each employee paid more than \$50,000 (b) Title, and average hours per week devoted to position (c) Compensation (d) Contributions to employee benefit plans and deferred compensation	-0-	-0-		-0-					L. Kraft	Ellen L
2 Compensation of five highest-paid employees (other than those included on line 1—see instruction "NONE." (a) Name and address of each employee paid more than \$50,000 (b) Title, and average hours per week devoted to position (c) Compensation (d) Contributions to employee benefit plans and deferred compensation							19			
2 Compensation of five highest-paid employees (other than those included on line 1—see instruction "NONE." (a) Name and address of each employee paid more than \$50,000 (b) Title, and average hours per week devoted to position (c) Compensation (d) Contributions to employee benefit plans and deferred compensation	-0-	-0-		-0-				eyer, MD	ond S. Sch	Raymo
"NONE." (a) Name and address of each employee paid more than \$50,000 (b) Title, and average hours per week devoted to position (c) Compensation (d) Contributions to employee benefit plans and deferred compensation						ioui/iiioiiii		rive, Linwood, NJ 08221-1544	Alexander	210
"NONE." (a) Name and address of each employee paid more than \$50,000 (b) Title, and average hours per week devoted to position (c) Compensation (d) Contributions to employee benefit plans and deferred compensation										
"NONE." (a) Name and address of each employee paid more than \$50,000 (b) Title, and average hours per week devoted to position (c) Compensation (d) Contributions to employee benefit plans and deferred compensation										
(a) Name and address of each employee paid more than \$50,000 (b) Title, and average hours per week devoted to position (c) Compensation (d) Contributions to employee benefit plans and deferred compensation	is). If none, enter	see instructions)	ine 1—s	uded on li	n those incl	(other th	employee	sation of five highest-paid emplo	-	2
(a) Name and address of each employee paid more than \$50,000 (c) Compensation employee benefit plans and deferred compensation									NONE	
devoted to position plans and deferred compensation	(e) Expense account,	employee benefit (neation	(a) Compos			+han \$50 000	address of each ampleyee paid mare than \$	(a) Nama a	
·	other allowances	plans and deferred	risauori	(c) Compe			triari \$50,000	address of each employee paid more than \$	(a) Name a	
	+									None
	+									
	 									
	+									
Total number of other employees paid over \$50,000	-0-	•		·		<u> </u>	50,000 .	other employees paid over \$50,000	number o	Total

(a) Name and address of each person paid more than \$50,000 (b) Type of service (c) Compensation Total number of others receiving over \$50,000 for professional services Part IX-A Summary of Direct Charitable Activities List the foundation's four largest direct charitable activities during the tax year, include relevant statistical information such as the number of organizations and other beneficiaries served, conferences convened, research papers produced, etc. 1 Directed Scientific Research: The New Hope Research Foundation conducted scientific research on gene vectors and specific methods of gene delivery for GM2 gangliosidosis therapy. The research is being conducted in areas of biochemical / in cellulo evaluation, genetic engineering, pre-clinical testing, and biomedical engineering and modeling. 2 Intellectual Property Development: The New Hope Research Foundation developed specific technology associated with delivery gine nectors to the central nervous system for the treatment of lysosomal storage diseases. To foundation now has worldwide rights to key intellectual property and has submitted additional US and PCT patert applications. 3 Education and Communication for Patients and Families: Maintained a web-site describing lysosomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 4 Scientific Research Project Management: Established a master plan for scientific research being explored by the Foundation of the scientific research being explored by the Foundation of the plant of the scientific research being explored by the Foundation of the plant of the scientific research being explored by the Foundation of the scientific research being explored by the Population of the plant of the scientific research being explored by the Population of the plant of the scientific research being explored by the Populati	3	and Contractors (continued) Five highest-paid independent contractors for professional services (see instructions). If none, enter "NONI	= "
Total number of others receiving over \$50,000 for professional services Description of the foundation's four largest direct charitable Activities List the foundation's four largest direct charitable activities during the tax year, include relevant statistical information such as the number of organizations and other beneficiaries served, conferences convened, research papers produced, etc. Directed Scientific Research: The New Hope Research Foundation conducted cicentific research on gene vectors and specific methods of gene delivery for GM2 gangliosidosis therapy. The research is being conducted in areas of biochemical / in cellulo evaluation, genetic engineering, pre-clinical testing, and biomedical engineering and modelling. Intellectual Property Development: The New Hope Research Foundation developed specific technology associated with delivery of gene vectors to the central nervous system for the treatment of lysosomal storage diseases. The Foundation now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications. 3 Education and Communication for Patients and Families. Maintained a web-site describing lysosomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. Scientific Research Project Management: Established a master plan for scientific research, conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount 1 None All other program-related investments. See instructions. 3 Non			
Total number of others receiving over \$50,000 for professional services 1 Directed Scientific Research: The New Hope Research Foundation conducted scientific research on gene vectors and specific methods of gene delivery for GM2 gangliosidosis therapy. The research is being conducted in areas of specific methods of gene delivery for GM2 gangliosidosis therapy. The research is being conducted in areas of biochemical / in cellulo evaluation, genetic engineering, pre-clinical testing, and biomedical engineering and modeling. 2 Intellectual Property Development: The New Hope Research Foundation developed specific technology associated with delivery of gene vectors to the central nervous system for the treatment of lysosomal storage diseases. The Foundation now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications. 3 Education and Communication for Patients and Families: Maintained a web-site describing lysosomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 3 Scientific Research Presults. Project management is Established a master plan for scientific research being explored by the research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-S Summary of Program-related investments made by the foundation during the tax year on lines 1 and 2. Amount All other program-related investments made by the foundation during the tax year on lines 1 and 2. Amount All other program-related investments. See instructions.	None		(1)
List the foundation's four largest direct charitable activities during the tax year. Include relevant statistical information such as the number of organizations and other beneficiaries served, conferences convened, research papers produced, etc. 1 Directed Scientific Research: The New Hope Research Foundation conducted scientific research on gene vectors and specific methods of gene delivery for GM2 gangliosidosis therapy. The research is being conducted in areas of biochemical / in cellulo evaluation, genetic engineering, pre-clinical testing, and biomedical engineering and modeling. 2 Intellectual Property Development: The New Hope Research Foundation developed specific technology associated with delivery of gene vectors to the central nervous system for the treatment of lysosomal storage diseases. The Foundation now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications. 3 Education and Communication for Patients and Families: Maintained a web-site describingly yosoomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 4 Scientific Research Project Management: Established a master plan for scientific research conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount All other program-related investments. See instructions.			
List the foundation's four largest direct charitable activities during the tax year. Include relevant statistical information such as the number of organizations and other beneficiaries served, conferences convened, research papers produced, etc. 1 Directed Scientific Research: The New Hope Research Foundation conducted scientific research on gene vectors and specific methods of gene delivery for GM2 gangliosidosis therapy. The research is being conducted in areas of biochemical / in cellulo evaluation, genetic engineering, pre-clinical testing, and biomedical engineering and modeling. 2 Intellectual Property Development: The New Hope Research Foundation developed specific technology associated with delivery of gene vectors to the central nervous system for the treatment of lysosomal storage diseases. The Foundation now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications. 3 Education and Communication for Patients and Families: Maintained a web-site describingly yosoomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 4 Scientific Research Project Management: Established a master plan for scientific research conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount All other program-related investments. See instructions.			
List the foundation's four largest direct charitable activities during the tax year. Include relevant statistical information such as the number of organizations and other beneficiaries served, conferences convened, research papers produced, etc. 1 Directed Scientific Research: The New Hope Research Foundation conducted scientific research on gene vectors and specific methods of gene delivery for GM2 gangliosidosis therapy. The research is being conducted in areas of biochemical / in cellulo evaluation, genetic engineering, pre-clinical testing, and biomedical engineering and modeling. 2 Intellectual Property Development: The New Hope Research Foundation developed specific technology associated with delivery of gene vectors to the central nervous system for the treatment of lysosomal storage diseases. The Foundation now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications. 3 Education and Communication for Patients and Families: Maintained a web-site describingly yosoomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 4 Scientific Research Project Management: Established a master plan for scientific research conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount All other program-related investments. See instructions.			
List the foundation's four largest direct charitable activities during the tax year. Include relevant statistical information such as the number of organizations and other beneficiaries served, conferences convened, research papers produced, etc. 1 Directed Scientific Research: The New Hope Research Foundation conducted scientific research on gene vectors and specific methods of gene delivery for GM2 gangliosidosis therapy. The research is being conducted in areas of biochemical / in cellulo evaluation, genetic enjournering, pre-clinical testing, and biomedical engineering and modeling. 2 Intellectual Property Development: The New Hope Research Foundation developed specific technology associated with delivery of gene vectors to the central nervous system for the treatment of lysosomal storage diseases. The Foundation now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications. 3 Education and Communication for Patients and Families: Maintained a web-site describing lysosomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 4 Scientific Research Project Management: Established a master plan for scientific research conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount All other program-related investments. See instructions.			
List the foundation's four largest direct charitable activities during the tax year. Include relevant statistical information such as the number of organizations and other beneficiaries served, conferences convened, research papers produced, etc. 1 Directed Scientific Research: The New Hope Research Foundation conducted scientific research on gene vectors and specific methods of gene delivery for GM2 gangliosidosis therapy. The research is being conducted in areas of biochemical / in cellulo evaluation, genetic enjournering, pre-clinical testing, and biomedical engineering and modeling. 2 Intellectual Property Development: The New Hope Research Foundation developed specific technology associated with delivery of gene vectors to the central nervous system for the treatment of lysosomal storage diseases. The Foundation now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications. 3 Education and Communication for Patients and Families: Maintained a web-site describing lysosomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 4 Scientific Research Project Management: Established a master plan for scientific research conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount All other program-related investments. See instructions.			
List the foundation's four largest direct charitable activities during the tax year. Include relevant statistical information such as the number of organizations and other beneficiaries served, conferences convened, research papers produced, etc. 1 Directed Scientific Research: The New Hope Research Foundation conducted scientific research on gene vectors and specific methods of gene delivery for GM2 gangliosidosis therapy. The research is being conducted in areas of biochemical / in cellulo evaluation, genetic enjournering, pre-clinical testing, and biomedical engineering and modeling. 2 Intellectual Property Development: The New Hope Research Foundation developed specific technology associated with delivery of gene vectors to the central nervous system for the treatment of lysosomal storage diseases. The Foundation now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications. 3 Education and Communication for Patients and Families: Maintained a web-site describing lysosomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 4 Scientific Research Project Management: Established a master plan for scientific research conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount All other program-related investments. See instructions.			
List the foundation's four largest direct charitable activities during the tax year. Include relevant statistical information such as the number of organizations and other beneficiaries served, conferences convened, research papers produced, etc. 1 Directed Scientific Research: The New Hope Research Foundation conducted scientific research on gene vectors and specific methods of gene delivery for GM2 gangliosidosis therapy. The research is being conducted in areas of biochemical / in cellulo evaluation, genetic engineering, pre-clinical testing, and biomedical engineering and modeling. 2 Intellectual Property Development: The New Hope Research Foundation developed specific technology associated with delivery of gene vectors to the central nervous system for the treatment of lysosomal storage diseases. The Foundation now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications. 3 Education and Communication for Patients and Families: Maintained a web-site describingly yosoomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 4 Scientific Research Project Management: Established a master plan for scientific research conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount All other program-related investments. See instructions.			
List the foundation's four largest direct charitable activities during the tax year. Include relevant statistical information such as the number of organizations and other beneficiaries served, conferences convened, research papers produced, etc. 1 Directed Scientific Research: The New Hope Research Foundation conducted scientific research on gene vectors and specific methods of gene delivery for GM2 gangliosidosis therapy. The research is being conducted in areas of biochemical / in cellulo evaluation, genetic engineering, pre-clinical testing, and biomedical engineering and modeling. 2 Intellectual Property Development: The New Hope Research Foundation developed specific technology associated with delivery of gene vectors to the central nervous system for the treatment of lysosomal storage diseases. The Foundation now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications. 3 Education and Communication for Patients and Families: Maintained a web-site describingly yosoomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 4 Scientific Research Project Management: Established a master plan for scientific research conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount All other program-related investments. See instructions.			
List the foundation's four largest direct charitable activities during the tax year. Include relevant statistical information such as the number of organizations and other beneficiaries served, conferences convened, research papers produced, etc. 1 Directed Scientific Research: The New Hope Research Foundation conducted scientific research on gene vectors and specific methods of gene delivery for GM2 gangliosidosis therapy. The research is being conducted in areas of biochemical / in cellulo evaluation, genetic enjournering, pre-clinical testing, and biomedical engineering and modeling. 2 Intellectual Property Development: The New Hope Research Foundation developed specific technology associated with delivery of gene vectors to the central nervous system for the treatment of lysosomal storage diseases. The Foundation now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications. 3 Education and Communication for Patients and Families: Maintained a web-site describing lysosomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 4 Scientific Research Project Management: Established a master plan for scientific research conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount All other program-related investments. See instructions.			
List the foundation's four largest direct charitable activities during the tax year. Include relevant statistical information such as the number of organizations and other beneficiaries served, conferences convened, research papers produced, etc. 1 Directed Scientific Research: The New Hope Research Foundation conducted scientific research on gene vectors and specific methods of gene delivery for GM2 gangliosidosis therapy. The research is being conducted in areas of biochemical / in cellulo evaluation, genetic engineering, pre-clinical testing, and biomedical engineering and modeling. 2 Intellectual Property Development: The New Hope Research Foundation developed specific technology associated with delivery of gene vectors to the central nervous system for the treatment of lysosomal storage diseases. The Foundation now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications. 3 Education and Communication for Patients and Families: Maintained a web-site describing lysosomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 4 Scientific Research Project Management: Established a master plan for scientific research, conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount All other program-related investments. See instructions.	Tota	I number of others receiving over \$50,000 for professional services	-0-
List the foundation's four largest direct charitable activities during the tax year. Include relevant statistical information such as the number of organizations and other beneficiaries served, conferences convened, research papers produced, etc. 1 Directed Scientific Research: The New Hope Research Foundation conducted scientific research on gene vectors and specific methods of gene delivery for GM2 gangliosidosis therapy. The research is being conducted in areas of biochemical / in cellulo evaluation, genetic engineering, pre-clinical testing, and biomedical engineering and modeling. 2 Intellectual Property Development: The New Hope Research Foundation developed specific technology associated with delivery of gene vectors to the central nervous system for the treatment of lysosomal storage diseases. The Foundation now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications. 3 Education and Communication for Patients and Families: Maintained a web-site describing lysosomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 4 Scientific Research Project Management: Established a master plan for scientific research, conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount All other program-related investments. See instructions.	Dai	t IX-A Summary of Direct Charitable Activities	
Directed Scientific Research: The New Hope Research Foundation conducted scientific research on gene vectors and specific methods of gene delivery for GM2 gangliosidosis therapy. The research is being conducted in areas of biochemical / in cellulo evaluation, genetic engineering, pre-clinical testing, and biomedical engineering and modeling. 2 Intellectual Property Development: The New Hope Research Foundation developed specific technology associated with delivery of gene vectors to the central nervous system for the treatment of lysosomal storage diseases. The Foundation now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications. 3 Education and Communication for Patients and Families: Maintained a web-site describing lysosomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 4 Scientific Research Project Management: Established a master plan for scientific research, conducted reviews of proposed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. All other program-related investments. See instructions. All other program-related investments. See instructions.	Га	Summary of Direct Chantable Activities	
specific methods of gene delivery for GM2 gangliosidosis therapy. The research is being conducted in areas of biochemical / in cellulo evaluation, genetic engineering, pre-clinical testing, and biomedical engineering and modeling. Intellectual Property Development: The New Hope Research Foundation developed specific technology associated with delivery of gene vectors to the central nervous system for the treatment of lysosomal storage diseases. The Foundation now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications. 3 Education and Communication for Patients and Families: Maintained a web-site describing lysosomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 4 Scientific Research Project Management: Established a master plan for scientific review of conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount All other program-related investments. See instructions. All other program-related investments. See instructions.			Expenses
biochemical / in cellulo evaluation, genetic engineering, pre-clinical testing, and biomedical engineering and modeling. Intellectual Property Development: The New Hope Research Foundation developed specific technology associated with delivery of gene vectors to the central nervous system for the treatment of lysosomal storage diseases. The Foundation now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications. Beducation and Communication for Patients and Families: Maintained a web-site describing lysosomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. Scientific Research Project Management: Established a master plan for scientific research, conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount None All other program-related investments. See instructions. None All other program-related investments. See instructions.	1	Directed Scientific Research: The New Hope Research Foundation conducted scientific research on gene vectors and	
2 Intellectual Property Development: The New Hope Research Foundation developed specific technology associated with delivery of gene vectors to the central nervous system for the treatment of lysosomal storage diseases. The Foundation now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications. 3 Education and Communication for Patients and Families: Maintained a web-site describing lysosomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 4 Scientific Research Project Management: Established a master plan for scientific research, conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount 1 None All other program-related investments. See instructions. 3 None All other program-related investments. See instructions.		specific methods of gene delivery for GM2 gangliosidosis therapy. The research is being conducted in areas of	\$ 85,863
delivery of gene vectors to the central nervous system for the treatment of lysosomal storage diseases. The Foundation now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications. 3 Education and Communication for Patients and Families: Maintained a web-site describing lysosomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 4 Scientific Research Project Management: Established a master plan for scientific research, conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount All other program-related investments. See instructions. 3 None -0-		biochemical / in cellulo evaluation, genetic engineering, pre-clinical testing, and biomedical engineering and modeling.	
now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications. 3 Education and Communication for Patients and Families: Maintained a web-site describing lysosomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 4 Scientific Research Project Management: Established a master plan for scientific research, conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount All other program-related investments. See instructions. 3 None All other program-related investments. See instructions.	2	Intellectual Property Development: The New Hope Research Foundation developed specific technology associated with	
3 Education and Communication for Patients and Families: Maintained a web-site describing lysosomal storage diseases and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 4 Scientific Research Project Management: Established a master plan for scientific research, conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount Amount All other program-related investments. See instructions. 3 None All other program-related investments. See instructions.		delivery of gene vectors to the central nervous system for the treatment of lysosomal storage diseases. The Foundation	31,350
and the underlying mechanisms of GM2 gangliosidosis. The site explains the scientific research being explored by the Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. Scientific Research Project Management: Established a master plan for scientific research, conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount Amount All other program-related investments. See instructions. None All other program-related investments. See instructions.		now has worldwide rights to key intellectual property and has submitted additional US and PCT patent applications.	
Foundation. Web-site maintenance is donated. The Foundation financed publication of three scientific manuscripts. 4 Scientific Research Project Management: Established a master plan for scientific research, conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount None -0: All other program-related investments. See instructions. None -0: -0: -0: -0: -0: -0: -0: -0	3	Education and Communication for Patients and Families: Maintained a web-site describing lysosomal storage diseases	
Scientific Research Project Management: Established a master plan for scientific research, conducted reviews of proposed research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount None All other program-related investments. See instructions. None -0- All other program-related investments. See instructions.			3,475
research, coordinated research being conducted at academic institutions, and provided critical review of completed research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount None All other program-related investments. See instructions. None All other program-related investments. See instructions.		-	
research results. Project management and the independent scientific review support was donated. Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount 1 None 2 All other program-related investments. See instructions. 3 None -0-	4		_
Part IX-B Summary of Program-Related Investments (see instructions) Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. Amount 1 None -0- All other program-related investments. See instructions. 3 None -0- This I Adulting the tax year on lines 1 and 2. Amount -0- -0- -0- -0- -0- -0- -0- -			-0-
Describe the two largest program-related investments made by the foundation during the tax year on lines 1 and 2. 1 None -0. All other program-related investments. See instructions. 3 None -0.			
1 None -0- 2			
All other program-related investments. See instructions. 3 None -0-			Amount
All other program-related investments. See instructions. None	1	None	0
All other program-related investments. See instructions. 3 None -0-			-0-
All other program-related investments. See instructions. 3 None -0-	•		
3 None -0.	2		
3 None -0.			
3 None -0.		other program-related investments. See instructions	
-0-	_		
	3		-0-
Total. Add lines 1 through 3			
	Tota	I. Add lines 1 through 3	-0-

Form **990-PF** (2015)

Part	see instructions.)	gri ioi	undations,
1	Fair market value of assets not used (or held for use) directly in carrying out charitable, etc.,		
	purposes:		
а	Average monthly fair market value of securities	1a	872,929
b	Average of monthly cash balances	1b	331,486
С	Fair market value of all other assets (see instructions)	1c	-0-
d	Total (add lines 1a, b, and c)	1d	1,204,415
е	Reduction claimed for blockage or other factors reported on lines 1a and		
	1c (attach detailed explanation)		
2	Acquisition indebtedness applicable to line 1 assets	2	-0-
3	Subtract line 2 from line 1d	3	1,204,415
4	Cash deemed held for charitable activities. Enter 11/2% of line 3 (for greater amount, see		
	instructions)	4	18,066
5	Net value of noncharitable-use assets. Subtract line 4 from line 3. Enter here and on Part V, line 4	5	1,186,349
6	Minimum investment return. Enter 5% of line 5	6	59,317
Part		ounda	ations
1	Minimum investment return from Part X, line 6	1	
2a	Tax on investment income for 2015 from Part VI, line 5		
b	Income tax for 2015. (This does not include the tax from Part VI.) 2b		
С	Add lines 2a and 2b	2c	
3	Distributable amount before adjustments. Subtract line 2c from line 1	3	
4	Recoveries of amounts treated as qualifying distributions	4	
5	Add lines 3 and 4	5	
6	Deduction from distributable amount (see instructions)	6	
7	Distributable amount as adjusted. Subtract line 6 from line 5. Enter here and on Part XIII,		
	line 1	7	
Part	XII Qualifying Distributions (see instructions)		
1	Amounts paid (including administrative expenses) to accomplish charitable, etc., purposes:		
' a	Expenses, contributions, gifts, etc.—total from Part I, column (d), line 26	1a	120,687
a b	Program-related investments—total from Part IX-B	1b	-0-
2	Amounts paid to acquire assets used (or held for use) directly in carrying out charitable, etc.,	10	
_	purposes	2	-0-
3	Amounts set aside for specific charitable projects that satisfy the:		
а	Suitability test (prior IRS approval required)	3a	-0-
a b	Cash distribution test (attach the required schedule)	3b	-0-
4	Qualifying distributions. Add lines 1a through 3b. Enter here and on Part V, line 8, and Part XIII, line 4	4	120,687
5	Foundations that qualify under section 4940(e) for the reduced rate of tax on net investment income.	•	.23,007
•	Enter 1% of Part I, line 27b (see instructions)	5	236
6	Adjusted qualifying distributions. Subtract line 5 from line 4	6	120,451
3	Note. The amount on line 6 will be used in Part V, column (b), in subsequent years when calculating		*
	qualifies for the section 4940(e) reduction of tax in those years.	y wne	mer me louridation

Part	VIII Undistributed Income (see instruction	ons) N/A — D e	esignated Private C	Operating Foundat	ion
1	Distributable amount for 2015 from Part XI, line 7	(a) Corpus	(b) Years prior to 2014	(c) 2014	(d) 2015
_					
2	Undistributed income, if any, as of the end of 2015:				
a	Enter amount for 2014 only				
b	Total for prior years: 20,20,20				
3	Excess distributions carryover, if any, to 2015:				
a	From 2010				
b	From 2011				
C	From 2012				
d	From 2013				
е	From 2014				
f	Total of lines 3a through e				
4	Qualifying distributions for 2015 from Part XII,				
	line 4: ▶ \$				
a	Applied to 2014, but not more than line 2a .				
b	Applied to undistributed income of prior years				
	(Election required—see instructions)				
С	Treated as distributions out of corpus (Election				
	required—see instructions)				
d	Applied to 2015 distributable amount				
_e	Remaining amount distributed out of corpus				
5	Excess distributions carryover applied to 2015				
	(If an amount appears in column (d), the same				
•	amount must be shown in column (a).)				
6	Enter the net total of each column as indicated below:				
а	Corpus. Add lines 3f, 4c, and 4e. Subtract line 5				
b	Prior years' undistributed income. Subtract				
	line 4b from line 2b				
С	Enter the amount of prior years' undistributed				
	income for which a notice of deficiency has				
	been issued, or on which the section 4942(a)				
	tax has been previously assessed				
d	Subtract line 6c from line 6b. Taxable				
	amount—see instructions				
е	Undistributed income for 2014. Subtract line				
	4a from line 2a. Taxable amount—see				
	instructions				
f	Undistributed income for 2015. Subtract lines				
	4d and 5 from line 1. This amount must be				
_	distributed in 2016				
7	Amounts treated as distributions out of corpus				
	to satisfy requirements imposed by section				
	170(b)(1)(F) or 4942(g)(3) (Election may be				
•	required—see instructions)				
8	Excess distributions carryover from 2010 not				
0	applied on line 5 or line 7 (see instructions) .				
9	Excess distributions carryover to 2016. Subtract lines 7 and 8 from line 6a				
46					
10	Analysis of line 9:				
а	Excess from 2011				
b	Excess from 2012				
С	Excess from 2013				
d	Excess from 2014				
е	Excess from 2015				

Part	XIV Private Operating Founda	tions (see instru	ctions and Part \	VII-A, question 9)	
1a	If the foundation has received a ruling	or determination	letter that it is a	private operating	,	
	foundation, and the ruling is effective fo	r 2015, enter the da	ate of the ruling .	🕨	August 1	7, 2007
b	Check box to indicate whether the four	ndation is a private	operating foundat	ion described in se	ection 🕢 4942(j)(3) or 4942(j)(5)
2a	Enter the lesser of the adjusted net	Tax year		Prior 3 years		(-) T - + - I
	income from Part I or the minimum	(a) 2015	(b) 2014	(c) 2013	(d) 2012	(e) Total
	investment return from Part X for each year listed	-0-	19,296	32,233	11,445	62,974
b	85% of line 2a	-0-	16,401	27,398	9,728	53,527
С	Qualifying distributions from Part XII,					
	line 4 for each year listed	120,687	150,578	138,072	105,169	514,506
d	Amounts included in line 2c not used directly					
	for active conduct of exempt activities	-0-	-0-	-0-	-0-	-0-
е	Qualifying distributions made directly					
	for active conduct of exempt activities.					
	Subtract line 2d from line 2c	120,687	150,578	138,072	105,169	514,506
3	Complete 3a, b, or c for the					
	alternative test relied upon:					
а	"Assets" alternative test-enter:					
	(1) Value of all assets					
	(2) Value of assets qualifying under					
	section 4942(j)(3)(B)(i)					
b	"Endowment" alternative test—enter 2/3 of minimum investment return shown in					
	Part X, line 6 for each year listed	39,545	35,265	23,811	17,297	115,918
С	"Support" alternative test—enter:					
	(1) Total support other than gross					
	investment income (interest, dividends, rents, payments on					
	securities loans (section					
	512(a)(5)), or royalties)					
	(2) Support from general public and 5 or more exempt					
	organizations as provided in					
	section 4942(j)(3)(B)(iii)					
	(3) Largest amount of support from					
	an exempt organization					
Dout	(4) Gross investment income	n (Complete th	is now only if th	a farmalation b	ad \$5 000 as ma	:
Part	XV Supplementary Information any time during the year-	• •		ie ioundation n	au \$5,000 or me	ore in assets at
1	Information Regarding Foundation		13.)			
' a	List any managers of the foundation	-	ited more than 2%	of the total contr	ibutions received	by the foundation
_	before the close of any tax year (but o					
John G	G. Keimel and Ellen L. Kraft				(// / /	
b	List any managers of the foundation	who own 10% or	more of the stoc	k of a corporation	n (or an equally la	rge portion of the
	ownership of a partnership or other en	ntity) of which the	foundation has a 1	0% or greater inte	erest.	
None						
2	Information Regarding Contribution	n, Grant, Gift, Loa	n, Scholarship, e	tc., Programs:		
	Check here ► ☐ if the foundation	-	·		-	
	unsolicited requests for funds. If the f		gifts, grants, etc. ((see instructions) t	o individuals or or	ganizations under
	other conditions, complete items 2a,	b, c, and d.				
	The name, address, and telephone nu	ımber or e-mail ad	ldress of the perso	on to whom application	ations should be a	ddressed:
	a. (Jack) Keimel ley Lake Court, North Oaks, MN 55127-621	9 Jack Keime	el@NewHopeResear	rch ora		
			<u> </u>			
b	The form in which applications should	I be submitted and	d information and r	materials they sho	uld include:	
Refere	nce the "New Hope Research Foundation -	Grant Proposal Proc	ess" at www.NewHo	peResearch.org/grai	nts	
	Any submission deadlines:	*				
	proposals are now being reviewed on a peri	odic basis throughou	t the year			

d Any restrictions or limitations on awards, such as by geographical areas, charitable fields, kinds of institutions, or other factors:

Supplementary Information (continued) Part XV **Grants and Contributions Paid During the Year or Approved for Future Payment** If recipient is an individual, show any relationship to any foundation manager Recipient Foundation Purpose of grant or status of Amount contribution recipient Name and address (home or business) or substantial contributor a Paid during the year The Hospital for Sick Children None NC Gene Therapy Research 2,393 555 University Avenue, Toronto, ON The University of North Carolina at Chapel Hill None PC Gene Therapy Research 16,438 Gene Therapy Center, Chapel Hill, NC 27599 Queen's University at Kingston NC None Gene Therapy Research 57,429 78 Fifth Field Company Lane, Kingston, ON За Approved for future payment The University of North Carolina at Chapel Hill PC Gene Therapy Research 106,000 None Gene Therapy Center, Chapel Hill, NC 27599 Queen's University at Kingston NC Gene Therapy Research 170,000 None 78 Fifth Field Company Lane, Kingston, ON

276,000

Pa							
Ente	r gro	ss amounts unless otherwise indicated.	(a) Business code	(b) Amount	(c) Exclusion code	(d) Amount	(e) Related or exempt function income
1	Pro	gram service revenue:	Dusiness code	Amount	LACIUSION COUC	Amount	(See instructions.)
		None				-0-	
	b						
	C						
	d						
	e						
	f						
	Ţ.,					0	
	-	Fees and contracts from government agencies				-0-	
2		mbership dues and assessments				-0-	
3		rest on savings and temporary cash investments			14	30	
4		dends and interest from securities			14	17,312	
5	Net	rental income or (loss) from real estate:					
	а	Debt-financed property					
	b	Not debt-financed property					
6	Net	rental income or (loss) from personal property					
7		er investment income					
8	Gair	or (loss) from sales of assets other than inventory			18	22,689	
9		income or (loss) from special events					
10		ss profit or (loss) from sales of inventory					
		er revenue: a					
• •	b						
	c						
	d						
40	е			0		40.021	0
	e Sub	ototal. Add columns (b), (d), and (e)				40,031	-0-
13	e Sub Tot	ototal. Add columns (b), (d), and (e) al. Add line 12, columns (b), (d), and (e)		-0-		40,031 13	-0- 40,031
13 (See	e Sub Tot wor	ototal. Add columns (b), (d), and (e)	is.)				_
13 (See Pa	e Sub Tot work	atotal. Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot wor t XV	atotal. Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031
13 (See Pai Lin	e Sub Tot work t X\ e No.	Add columns (b), (d), and (e)	ns.) Accomplishm	ent of Exemp	t Purposes	13	40,031

Form 990-I		,		pe Research Foundat Insfers To and Transacti		d Relationships With Noncha	aritable	Page 1
			rganizations					
						any other organization described		Yes No
			ie Code (other than	section 501(c)(3) organization	ons) or in	section 527, relating to political	7	
	•	izations?					7	
		-	-	to a noncharitable exempt of	_		7	
-							1a(1)	/
•	` '	ther assets .					1a(2)	~
		transactions:	! 	! t!			11. (4)	
•	. ,		o a noncharitable exe	. 0			1b(1)	4
				itable exempt organization . ner assets			1b(2)	4
-			• •	ner assets			1b(3) 1b(4)	4
-			•				1b(4) 1b(5)	4
-		•					1b(5) 1b(6)	- V
-				. •		· · · · · · · · · · · · · · · · · · ·	1D(6)	1
		•		· · · · · · · · · · · · · · · · · · ·		s e. Column (b) should always sho		
						e. Column (b) should always sho on. If the foundation received less		
						e of the goods, other assets, or se		
(a) Line n) Amount involved		charitable exempt organization		escription of transfers, transactions, and sha		
N/A	- ' '	N/A	1 ' '		N/A			5.
	_				+			-
	+				+			
	+				+			
	+		+		+			
	+		+		+			
	+		+		+			
	+		+		+			
	+		+		+			
	+		 		+			
	+		+					
	+		+		+			
	+		+					
	+		+					
	+		+		+			
	+		+		+			
2a Is	the	foundation dire	and or indirectly a	effiliated with or related to.	one or m	nore tax-exempt organizations		
				(other than section 501(c)(3))			□ V _P	✓ No
			e following schedule		Or ni e.	MON OZ7:	I 60 ,	W INC
	1 10.	(a) Name of organi		(b) Type of organizatio	-n	(c) Description of relation	ionehin	
N/A		(a) Nume 5 5	IZation	N/A		N/A	Люпр	
<u>""</u>				INA		IN/A		
				+				
				+		_		
				+				
	Inder		1 deplays that I have examin	The seture including accompanying	~ cohedules /	and statements, and to the best of my knowled	and be	-linf it is t
				ned this return, including accompanying than taxpayer) is based on all informatio		preparer has any knowledge.		
igii	1	1 4	Keinel	\		May the I	IRS discuss	
lere	. 7 🔪	1-1-11	Lenuc	11/14/2016 C	Chairman / F		ructions)?	

Sign Here) (ature of officer or trustee	11/14/2016 Date	Chairman / Pres	,	wleage.	with the	IRS discuss this return preparer shown below ructions)? Yes No
Paid Prepa	<i>C</i> rer	Print/Type preparer's name	Preparer's signature		Date	Che self	eck if employed	PTIN
Use O		Firm's name ►				Firm's EIN	>	
000 0	y	Firm's address ▶				Phone no.		
								- 000 DE (22.5)

87-0790903 Page 1

Statement 1: Legal Fees -- Form 990-PF, Part I, Line 16a

Legal Fees – Patent and Licensing	(a)	(b)	(c)	(d)
	Expenses	Investment	Adjusted	Charitable
	Per Books	Income	Net Income	Purposes
Patent Applications and Licensing	31,214	0	0	31,214
Total	31,214	0	0	31,214

Statement 2: Taxes -- Form 990-PF, Part I, Line18

Taxes – Related to investment	(a)	(b)	(c)	(d)
income	Expenses	Investment	Adjusted	Charitable
	Per Books	Income	Net Income	Purposes
Excise tax (Form 990-PF)	9,678	9,678	9,678	0
State of Minnesota	25	25	25	0
Total	9,703	9,703	9,703	0

Statement 3: Other Expenses -- Form 990-PF, Part I, Line 23

Other Expenses	(a)	(b)	(c)	(d)
	Expenses	Investment	Adjusted	Charitable
	Per Books	Income	Net Income	Purposes
Research Supplies – Peptide Pool	2,673	0	0	2673
Research scientist recognition	52	0	0	52
Document preparation / delivery	25	8	8	17
Total	2,750	8	8	2,742

Statement 4: Investments in Corporate Stocks -- Form 990-PF, Part II, Line 10b

Corporate Stocks	(a)	(b)	(c)	
·	Beginning of Year	End of Year	End of Year	
	Book Value	Book Value	Fair Market Value	
Medtronic, PLC	792,585	330,885	373,111	
SPDR Trust Series 1 ETF	-0-	207,283	230,422	
Total	792,585	538,168	603,533	

Statement 5: Other Investments -- Form 990-PF, Part II, Line 13

Other Investments	(2)	(b)	(c)
Other investments	(a)	(-)	(c)
	Beginning of Year	End of Year	End of Year
	Book Value	Book Value	Fair Market Value
Certificate of Deposit	125,000	0	0
Total	125,000	0	0